248 research outputs found
Recommended from our members
Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42.
Well-differentiated papillary mesothelioma is an uncommon mesothelial neoplasm that most frequently arises in the peritoneal cavity of women of reproductive age. Whereas malignant mesothelioma is an aggressive tumor associated with poor outcome, well-differentiated papillary mesothelioma typically exhibits indolent behavior. However, histologically differentiating between these two entities can be challenging, necessitating the development of distinguishing biomarkers. While the genetic alterations that drive malignant mesothelioma have recently been determined, the molecular pathogenesis of well-differentiated papillary mesothelioma is unknown. Here we performed genomic profiling on a cohort of ten well-differentiated papillary mesothelioma of the peritoneum. We identified that all tumors harbored somatic missense mutations in either the TRAF7 or CDC42 genes, and lacked alterations involving BAP1, NF2, CDKN2A, DDX3X, SETD2, and ALK that are frequent in malignant mesothelioma. We recently identified that another mesothelial neoplasm, adenomatoid tumor of the genital tract, is genetically defined by somatic missense mutations in the TRAF7 gene, indicating a shared molecular pathogenesis between well-differentiated papillary mesothelioma and adenomatoid tumors. To the best of our knowledge, well-differentiated papillary mesothelioma is the first human tumor type found to harbor recurrent mutations in the CDC42 gene, which encodes a Rho family GTPase. Immunohistochemistry demonstrated intact BAP1 expression in all cases of well-differentiated papillary mesothelioma, indicating that this is a reliable marker for distinguishing well-differentiated papillary mesothelioma from malignant mesotheliomas that frequently display loss of expression. Additionally, all well-differentiated papillary mesothelioma demonstrated robust expression of L1 cell adhesion molecule (L1CAM), a marker of NF-kB pathway activation, similar to that observed in adenomatoid tumors. In contrast, we have previously shown that L1CAM staining is not observed in normal mesothelial cells and malignant mesotheliomas of the peritoneum. Together, these studies demonstrate that well-differentiated papillary mesothelioma is genetically defined by mutually exclusive mutations in TRAF7 and CDC42 that molecularly distinguish this entity from malignant mesothelioma
Recommended from our members
Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation.
Adenomatoid tumors are the most common neoplasm of the epididymis, and histologically similar adenomatoid tumors also commonly arise in the uterus and fallopian tube. To investigate the molecular pathogenesis of these tumors, we performed genomic profiling on a cohort of 31 adenomatoid tumors of the male and female genital tracts. We identified that all tumors harbored somatic missense mutations in the TRAF7 gene, which encodes an E3 ubiquitin ligase belonging to the family of tumor necrosis factor receptor-associated factors (TRAFs). These mutations all clustered into one of five recurrent hotspots within the WD40 repeat domains at the C-terminus of the protein. Functional studies in vitro revealed that expression of mutant but not wild-type TRAF7 led to increased phosphorylation of nuclear factor-kappa B (NF-kB) and increased expression of L1 cell adhesion molecule (L1CAM), a marker of NF-kB pathway activation. Immunohistochemistry demonstrated robust L1CAM expression in adenomatoid tumors that was absent in normal mesothelial cells, malignant peritoneal mesotheliomas and multilocular peritoneal inclusion cysts. Together, these studies demonstrate that adenomatoid tumors of the male and female genital tract are genetically defined by TRAF7 mutation that drives aberrant NF-kB pathway activation
Variability of Dosing and Number of Medications Needed to Achieve Adequate Sedation in Mechanically Ventilated Pediatric Intensive Care Patients.
Children admitted to the pediatric intensive care unit (PICU) often require multiple medications to achieve comfort and sedation. Although starting doses are available, these medications are typically titrated to the desired effect. Both oversedation and undersedation are associated with adverse events. The aim of this retrospective study was to evaluate cumulative medication burden necessary to achieve comfort in patients in the PICU and determine relevant predictors of medication needs. In order to account for all of the sedative medications, z-scores were used to assess the population average dose of each medication and compare each patient day to this population average. Sedation regimens for 130 patients in the PICU were evaluated. Mean overall infusion rates of fentanyl, morphine, and hydromorphone were 1.67 ± 0.81 µg/kg/hour, 0.12 ± 0.08 mg/kg/hour, and 17.84 ± 13.4 µg/kg/hour, respectively. The mean infusion rate of dexmedetomidine was 0.59 ± 0.28 µg/kg/hour, and midazolam was 0.14 ± 0.1 mg/kg/hour. Summation z-sores were used to rank the amount of sedation medication needed to achieve comfort for each individual patient for his/her PICU stay in relation to the entire sample. Patient age, weight, and length of mechanical ventilation were all significant predictors of sedation requirement. This study will provide data necessary to develop a model of cumulative medication burden needed to achieve appropriate sedation in this population. This descriptive model in appropriately ranking patients based on sedative needs is the first step in exploring potential genetic factors that may provide an insight into homing in on the appropriate sedation regimen
Effect of Selenium Nanoparticle Size on IL-6 Detection Sensitivity in a Lateral Flow Device
Sepsis is the body’s response to an infection.
Existing
diagnostic testing equipment is not available in primary care settings
and requires long waiting times. Lateral flow devices (LFDs) could
be employed in point-of-care (POC) settings for sepsis detection;
however, they currently lack the required sensitivity. Herein, LFDs
are constructed using 150–310 nm sized selenium nanoparticles
(SeNPs) and are compared to commercial 40 nm gold nanoparticles (AuNPs)
for the detection of the sepsis biomarker interleukin-6 (IL-6). Both
310 and 150 nm SeNPs reported a lower limit of detection (LOD) than
40 nm AuNPs (0.1 ng/mL compared to 1 ng/mL), although at the cost
of test line visual intensity. This is to our knowledge the first
use of larger SeNPs (>100 nm) in LFDs and the first comparison
of
the effect of the size of SeNPs on assay sensitivity in this context.
The results herein demonstrate that large SeNPs are viable alternatives
to existing commercial labels, with the potential for higher sensitivity
than standard 40 nm AuNPs
Trans-Ethnic Mapping of BANK1 Identifies Two Independent SLE-Risk Linkage Groups Enriched for Co-Transcriptional Splicing Marks
BANK1 is a susceptibility gene for several systemic autoimmune diseases in several populations.
Using the genome-wide association study (GWAS) data from Europeans (EUR) and African Americans
(AA), we performed an extensive fine mapping of ankyrin repeats 1 (BANK1). To increase the SNP
density, we used imputation followed by univariate and conditional analysis, combinedwith a haplotypic
and expression quantitative trait locus (eQTL) analysis. The data from Europeans showed that the
associated region was restricted to a minimal and dependent set of SNPs covering introns two and three,
and exon two. In AA, the signal found in the Europeans was split into two independent effects. All of
the major risk associated SNPs were eQTLs, and the risks were associated with an increased BANK1 gene
expression. Functional annotation analysis revealed the enrichment of repressive B cell epigenomicmarks
(EZH2 and H3K27me3) and a strong enrichment of splice junctions. Furthermore, one eQTL located
in intron two, rs13106926, was found within the binding site for RUNX3, a transcriptional activator.
These results connect the local genome topography, chromatin structure, and the regulatory landscape of
BANK1 with co-transcriptional splicing of exon two. Our data defines a minimal set of risk associated
eQTLs predicted to be involved in the expression of BANK1 modulated through epigenetic regulation
and splicing. These findings allow us to suggest that the increased expression of BANK1 will have an
impact on B-cell mediated disease pathways.The work presented in this paper has been supported by the Ministerio de EconomÃa y Competitividad,
Spain (SAF2016-78631-P), partly co-financed by FEDER funds of the European Union, the Gustaf den V:e-80-Ã¥rs
Fond and the Swedish Association against Rheumatism to M.E.A-R. In addition, this work was financed by the
NIH P01 grant P01-AI-083194 to C.D.L., J.B.H., R.K., and M.E.A-R. JBH: NIH grants: R01 AI024717, U01 HG00866,
P30 AR070549 and U01 AI130830 and the US Department of Veterans Affairs: I01 BX001834.C.D.L.: Center for
Public Health Genomics. R.K.: NIH grant R01-AR33062. J.A.J.: NIH grants U54GM104938, P30AR053483
The Unknown and Awakening Europe
Program for the fourth annual RISD Cabaret held in the Cellar at the top of the Waterman Building. Design by Daniel Kraft.https://digitalcommons.risd.edu/liberalarts_cabaret_programs/1003/thumbnail.jp
Recommended from our members
PATH-38. ROSETTE-FORMING GLIONEURONAL TUMOR IS DEFINED BY FGFR1 ACTIVATING ALTERATIONS WITH FREQUENT ACCOMPANYING PI3K AND MAPK PATHWAY MUTATIONS
Abstract
BACKGROUND
Rosette-forming glioneuronal tumor (RGNT) is an uncommon CNS tumor originally described in the fourth ventricle characterized by a low-grade glial neoplasm admixed with a rosette-forming neurocytic component.
METHODS
We reviewed clinicopathologic features of 42 patients with RGNT. Targeted next-generation sequencing was performed, and genome-wide methylation profiling is underway.
RESULTS
The 20 male and 22 female patients had a mean age of 25 years (range 3–47) at time of diagnosis. Tumors were located within or adjacent to the lateral ventricle (n=16), fourth ventricle (15), third ventricle (9), and spinal cord (2). All 31 tumors assessed to date contained FGFR1 activating alterations, either in-frame gene fusion, kinase domain tandem duplication, or hotspot missense mutation in the kinase domain (p.N546 or p.K656). While 7 of these 31 tumors harbored FGFR1 alterations as the solitary pathogenic event, 24 contained additional pathogenic alterations within PI3-kinase or MAP kinase pathway genes: 5 with additional PIK3CA and NF1 mutations, 4 with PIK3CA mutation, 3 with PIK3R1 mutation (one of which also contained focal RAF1 amplification), 5 with PTPN11 mutation (one with additional PIK3R1 mutation), and 2 with NF1 deletion. The other 5 cases demonstrated anaplastic features including hypercellularity and increased mitotic activity. Among these anaplastic cases, 3 harbored inactivating ATRX mutations and two harbored CDKN2A homozygous deletion, in addition to the FGFR1 alterations plus other PI3-kinase and MAP kinase gene mutations seen in those RGNT without anaplasia.
CONCLUSION
Independent of ventricular location, RGNT is defined by FGFR1 activating mutations or rearrangements, which are frequently accompanied by mutations involving PIK3CA, PIK3R1, PTPN11, NF1, and KRAS. Whereas pilocytic astrocytoma and ganglioglioma are characterized by solitary activating MAP kinase pathway alterations (e.g. BRAF fusion or mutation), RGNT are genetically more complex with dual PI3K-Akt-mTOR and Ras-Raf-MAPK pathway activation. Rare anaplastic examples may show additional ATRX and/or CDKN2A inactivation
The Science Case for an Extended Spitzer Mission
Although the final observations of the Spitzer Warm Mission are currently
scheduled for March 2019, it can continue operations through the end of the
decade with no loss of photometric precision. As we will show, there is a
strong science case for extending the current Warm Mission to December 2020.
Spitzer has already made major impacts in the fields of exoplanets (including
microlensing events), characterizing near Earth objects, enhancing our
knowledge of nearby stars and brown dwarfs, understanding the properties and
structure of our Milky Way galaxy, and deep wide-field extragalactic surveys to
study galaxy birth and evolution. By extending Spitzer through 2020, it can
continue to make ground-breaking discoveries in those fields, and provide
crucial support to the NASA flagship missions JWST and WFIRST, as well as the
upcoming TESS mission, and it will complement ground-based observations by LSST
and the new large telescopes of the next decade. This scientific program
addresses NASA's Science Mission Directive's objectives in astrophysics, which
include discovering how the universe works, exploring how it began and evolved,
and searching for life on planets around other stars.Comment: 75 pages. See page 3 for Table of Contents and page 4 for Executive
Summar
- …